Cleerly to Present New Clinical Evidence on AI-Enabled CCTA at ACC.23/WCC
Cleerly to Present New Clinical Evidence on AI-Enabled CCTA at ACC.23/WCC Research shows accuracy and effectiveness of Cleerly’s personalized...
Cleerly is aware of the lawsuit filed by Heartflow. We are confident in our extensive and well-established intellectual property portfolio and the originality of our technology.
Cleerly has published landmark clinical science that has redefined how cardiovascular disease is understood and treated, which has formed the basis of our novel technologies that provide physicians with actionable insights into their patients’ heart health.
Cleerly was founded on a mission to create a world without heart attacks, and we have never been more focused in our mission and committed to the patients and physicians who count on us.
For any questions, please reach out to press@cleerlyhealth.com
Cleerly to Present New Clinical Evidence on AI-Enabled CCTA at ACC.23/WCC Research shows accuracy and effectiveness of Cleerly’s personalized...
Cleerly Hires Udo Hoffmann, MD MPH as Chief Scientific Officer Cardiovascular clinical trial expert brings AI imaging experience to lead research...
New alliance combines Cleerly’s AI-enabled approach to identifying early signs of heart disease with Heartbeat Health’s nationwide footprint of...
Cleerly introduces Proxy solution to improve heart disease imaging workflows Proxy allows for seamless data transmission and improved AI-based plaque...